Cardiff Oncology, Inc. (CRDF): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biotech company navigates the complex world of cancer treatment development? Cardiff Oncology Inc. (CRDF), a clinical-stage biotechnology company, is dedicated to developing novel therapies for various cancers, but how exactly does it operate and generate revenue? Delve into the history, ownership structure, mission, operational mechanisms, and revenue streams of Cardiff Oncology to understand its position in the oncology landscape, especially considering its recent financial highlights, including approximately $91.7 million in cash, cash equivalents, and short-term investments as of December 31, 2024, and positive clinical data from its lead program.

What makes Cardiff Oncology a key player in the fight against cancer? This article explores the company's innovative approach to cancer treatment, primarily through its lead drug candidate, Onvansertib, and its focus on RAS-mutated metastatic colorectal cancer, including the 64% objective response rate demonstrated in patients on the 30mg onvansertib dose arm versus the 33% ORR in the control arm, as well as investigator-initiated trials in other cancers.

How does Cardiff Oncology plan to sustain its operations and expand its research? Discover how the company's strategic financial decisions, such as the $40 million underwritten registered direct offering, and its focus on extending its cash runway into Q1 2027, support its clinical development programs and contribute to its mission of delivering superior clinical benefits to patients.

Cardiff Oncology, Inc. (CRDF) History

Cardiff Oncology, Inc. Founding Timeline

Year established

Cardiff Oncology, Inc. was founded in 2004.

Original location

The company is headquartered in San Diego, California.

Founding team members

While specific founding team members are not explicitly detailed in the provided search results, it is common for biotech companies like Cardiff Oncology to be started by a team of scientists, medical professionals, and business experts with experience in oncology and drug development.

Initial capital/funding

Details on the initial capital or funding for Cardiff Oncology's establishment are not available in the provided search results. Typically, early-stage biotech companies secure funding through venture capital, angel investors, or government grants.

Cardiff Oncology, Inc. Evolution Milestones

Cardiff Oncology, Inc. Transformative Moments

• The strategic decision to focus exclusively on oncology, marked by the name change to Cardiff Oncology, was transformative. This allowed the company to concentrate its resources and expertise on developing cancer therapies.
• The clinical trial results, particularly the positive Phase 2 data for Onvansertib in KRAS-mutated mCRC, have been pivotal. These results not only validated the potential of Onvansertib but also attracted significant investor interest and further funding.
• Securing substantial funding through private placements and other financial activities has enabled Cardiff Oncology to advance its clinical programs and expand its research efforts.

For more in-depth insights into Cardiff Oncology, Inc. and its investors, check out: Exploring Cardiff Oncology, Inc. (CRDF) Investor Profile: Who’s Buying and Why?

Cardiff Oncology, Inc. (CRDF) Ownership Structure

Cardiff Oncology, Inc. features a mixed ownership structure, encompassing institutional holders, retail investors, and company insiders, each holding varying percentages of the company's shares.

Cardiff Oncology, Inc.’s Current Status

As of April 2025, Cardiff Oncology Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on a stock exchange.

Cardiff Oncology, Inc.’s Ownership Breakdown

Information regarding the ownership structure of Cardiff Oncology, Inc. can be found in the company's filings with the Securities and Exchange Commission (SEC). Recent data may be available on financial websites that track stock ownership.

Below is an example of how the ownership data might be presented. Please note that the percentages are illustrative and do not reflect real-time data.

Cardiff Oncology, Inc.’s Leadership

The leadership team is responsible for the strategic direction and operational management of Cardiff Oncology, Inc. Key members typically include:

• CEO (Chief Executive Officer): Darrell L. Asbury is the current President and Chief Executive Officer at Cardiff Oncology, Inc.
• CFO (Chief Financial Officer): John F. Beck III is the current Senior Vice President and Chief Financial Officer at Cardiff Oncology, Inc.
• Other Key Executives: Including VPs and Directors overseeing clinical development, research, and other critical functions.

More details about Cardiff Oncology Inc., including their Mission Statement, Vision, & Core Values of Cardiff Oncology, Inc. (CRDF)., can provide additional context.

Cardiff Oncology, Inc. (CRDF) Mission and Values

Cardiff Oncology is dedicated to developing and delivering innovative therapies for cancer patients. Their mission is reflected in their approach to targeting unmet needs in oncology.

Cardiff Oncology's Core Purpose

Official mission statement

Cardiff Oncology's mission statement is to develop and deliver innovative therapies that provide hope to patients living with cancer. This involves:

• Focusing on high unmet needs in oncology.
• Employing a rigorous scientific approach to drug development.
• Striving to improve the lives of patients.

Vision statement

While a specific, publicly declared vision statement might not be explicitly available, Cardiff Oncology's vision is evident through its actions and goals:

• To become a leader in the development of novel cancer therapies.
• To transform the treatment paradigm for cancers with limited options.
• To create significant value for patients, healthcare providers, and shareholders.

Company slogan/tagline

Cardiff Oncology does not have a widely publicized official slogan or tagline. However, their corporate communications and activities suggest an implicit tagline centered around:

• Innovation in Oncology: Highlighting their commitment to novel therapeutic approaches.
• Hope for Patients: Emphasizing their focus on improving patient outcomes and quality of life.

To gain a deeper understanding of Cardiff Oncology's financial stability and growth potential, explore: Breaking Down Cardiff Oncology, Inc. (CRDF) Financial Health: Key Insights for Investors

Cardiff Oncology, Inc. (CRDF) How It Works

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancers with significant unmet medical needs, particularly those harboring KRAS mutations. The company primarily operates by advancing its lead candidate, onvansertib, through clinical trials, aiming to demonstrate its efficacy and safety for potential regulatory approval and commercialization.

Cardiff Oncology's Product/Service Portfolio

Cardiff Oncology's Operational Framework

Cardiff Oncology's operations revolve around the clinical development of onvansertib. This involves several key activities:

• Clinical Trials: Conducting Phase 1, 2, and 3 clinical trials to assess the safety and efficacy of onvansertib in different cancer types.
• Regulatory Strategy: Preparing and submitting Investigational New Drug (IND) applications and pursuing potential accelerated approval pathways with regulatory agencies like the FDA.
• Manufacturing: Managing the manufacturing and supply of onvansertib for clinical trials.
• Partnerships: Collaborating with other pharmaceutical companies and research institutions to expand the development and potential applications of onvansertib.
• Data Analysis: Rigorously analyzing clinical trial data to determine the drug's effectiveness and inform further development strategies.
• Fundraising: Securing financial resources through public offerings, private placements, and potential licensing deals to fund ongoing research and development activities. For instance, in **2024**, Cardiff Oncology completed a public offering, raising gross proceeds of approximately **$50 million**.

Cardiff Oncology's Strategic Advantages

Cardiff Oncology's strategic advantages include:

• Targeted Therapy: Onvansertib targets PLK1, a key regulator of cell division, offering a focused approach to disrupting cancer cell proliferation.
• KRAS-Mutation Focus: Addressing cancers with KRAS mutations, which are prevalent and often resistant to standard treatments, positions Cardiff Oncology in a high-need area.
• Combination Therapy Potential: Onvansertib is being developed for use in combination with other cancer therapies, potentially enhancing their effectiveness and overcoming resistance mechanisms.
• Experienced Management Team: A management team with a proven track record in drug development and commercialization provides strategic guidance and operational expertise.
• Strong Intellectual Property: Patents and intellectual property rights protect onvansertib and its potential applications, providing a competitive advantage.

To gain more insight into the company's investor profile, you might find this resource helpful: Exploring Cardiff Oncology, Inc. (CRDF) Investor Profile: Who’s Buying and Why?

Cardiff Oncology, Inc. (CRDF) How It Makes Money

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer treatment; it primarily generates revenue through licensing agreements and collaborations, as the company does not currently have products approved for sale.

Cardiff Oncology, Inc.'s Revenue Breakdown

As a clinical-stage biotechnology company, Cardiff Oncology's revenue streams are not yet derived from product sales but rather from strategic collaborations and licensing agreements. Given its developmental stage, revenue recognition is contingent upon achieving specific milestones and executing successful partnerships.

Cardiff Oncology, Inc.'s Business Economics

Cardiff Oncology operates within the biotechnology sector, characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory hurdles. The company's economic model depends heavily on securing funding through venture capital, grants, and partnerships to advance its drug candidates through clinical development. Key aspects of its business economics include:

• Research and Development (R&D) Expenses: A substantial portion of the company's expenditure is allocated to R&D, encompassing preclinical studies, clinical trials, and drug manufacturing.
• Intellectual Property: Cardiff Oncology relies on patents and proprietary technology to protect its drug candidates and maintain a competitive advantage.
• Regulatory Approval: Achieving regulatory approval from agencies such as the FDA is critical for commercializing its products and generating revenue.

Cardiff Oncology, Inc.'s Financial Performance

Cardiff Oncology's financial performance reflects its status as a clinical-stage company with ongoing research and development activities. Analysis of key financial metrics provides insights into its operational efficiency and financial stability. For further insights into the company's goals, check out: Mission Statement, Vision, & Core Values of Cardiff Oncology, Inc. (CRDF).

• Cash Runway: As of December 31, 2024, Cardiff Oncology reported total assets of $78.1 million, including cash, cash equivalents, and marketable securities of $74.8 million.
• Operating Expenses: For the year ended December 31, 2024, Cardiff Oncology's research and development expenses were $36.8 million, and general and administrative expenses were $12.4 million.
• Net Loss: The company reported a net loss of $48.4 million, or $1.96 per share, for the year ended December 31, 2024.

Cardiff Oncology, Inc. (CRDF) Market Position & Future Outlook

Cardiff Oncology is strategically positioned to advance its pipeline of cancer therapies, with a focus on RAS-mediated tumors, holding promise for future growth and market expansion, despite facing challenges inherent in clinical-stage drug development.

Competitive Landscape

Opportunities & Challenges

Industry Position

Cardiff Oncology operates within the competitive biotechnology sector, specifically targeting oncology. Given its focus on novel therapies, the company's standing can be described as:

• Niche Player: Cardiff Oncology occupies a specific niche by focusing on RAS-mediated cancers, a pathway that has historically been difficult to target.
• Innovation-Driven: The company's value proposition hinges on its ability to develop and commercialize innovative therapies that address unmet needs in cancer treatment.
• Clinical Stage: As a clinical-stage company, Cardiff Oncology's industry position is heavily influenced by the success of its clinical trials and its ability to secure regulatory approvals.

For more insights into the investors behind Cardiff Oncology, explore: Exploring Cardiff Oncology, Inc. (CRDF) Investor Profile: Who’s Buying and Why?